Update on the Management of Takayasu Arteritis

Rheumatologists primarily manage Takayasu arteritis with glucocorticoids, but evidence suggests conventional immunosuppressive drugs and tumor necrosis factor inhibitors may also be beneficial. Unfortunately, only two randomized controlled trials have specifically addressed the treatment of Takayasu arteritis and did not constitute high-quality evidence. One of these trials did find that patients did better on tocilizumab than placebo, but tocilizumab failed the primary endpoint for time to relapse.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan;79(1):19–30.
Águeda AF, Monti S, Luqmani RA, et al. Management of Takayasu arteritis: A systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open. 2019 Sep 23;5(2):e001020. eCollection 2019.

How this rare form of large-vessel vasculitis affects different portions, branches of aorta and ways to diagnose, treat and manage the disease

LONDON—New therapies are emerging for the two main forms of large-vessel vasculitis, giant cell arteritis (GCA) and Takayasu’s arteritis—particularly biologic therapies. But for just about every available treatment gap, drawbacks or limited evidence remain, with the results needing to be borne out in larger trials, an expert said at the Annual Congress of the European…

Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.

The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

Fellow’s Forum Case Report: Takayasu’s Arteritis

New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

3 New Vasculitis Guidelines Discussed

Related Articles